Developer docs
API playgroundTry for free, no card

Search company profiles

SISCAPA Assay Technologies

Full company profile

uuid0000zmj

Namestring
SISCAPA Assay Technologies
Legal namestring
SISCAPA Assay Technologies, Inc.
Websiteurl
siscapa.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

SISCAPA Assay Technologies, Inc. is a Washington, DC-based private proteomics company founded in 2011 that develops and commercializes the SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) immuno-affinity mass spectrometry platform for quantitative measurement of protein biomarkers and therapeutic proteins. The technology combines high-affinity anti-peptide antibody enrichment of proteolytically derived surrogate peptides with stable isotope-labeled internal standards and targeted mass spectrometry detection, enabling interference-free quantification across a >10^10-fold dynamic range, sub-ng/mL sensitivity in complex matrices, and multiplexing of up to ~50 assays in a single run. The company has built a catalog of more than 350 validated assays against diverse protein biomarkers, including FDA-cleared clinical markers such as thyroglobulin, where its clinical test has produced over 150,000 patient results through reference laboratories worldwide.

SISCAPA monetizes primarily through professional services: custom assay development (peptide selection, antibody reagent development, automated workflow optimization, and transfer to client CROs) and CRO-style analytical services including non-GLP sample analysis and multiplex panel execution. It also sells catalog assays outright and operates the LongitudeDX sub-brand, which combines dried blood spot sampling, wearable sensor integration, and the SampleDiary module for high-frequency longitudinal biomarker monitoring. Customers are pharmaceutical and biotechnology companies, gene therapy developers, diagnostic firms, academic researchers, and clinical reference laboratories. A wholly-owned Canadian subsidiary supports North American operations, and a June 2026 strategic collaboration with Biognosys extends assay accessibility into regulated clinical trial environments through Biognosys' CRO infrastructure.

The company is founder-controlled (N. Leigh Anderson, CEO and inventor of SISCAPA; Terry Pearson, CSO; Constance Seniff, VP Business Operations), with board oversight from seasoned diagnostics operators including a former Olink Proteomics chair and a biotech entrepreneur-investor. Capitalization has been modest: three disclosed funding rounds totaling roughly $3.56M between 2012 and 2025. The company competes on scientific depth and assay breadth rather than scale, with no publicly disclosed revenue and no AI/ML layer on top of its chemistry platform.

Short descriptiontext

SISCAPA Assay Technologies develops and commercializes the SISCAPA immuno-affinity mass spectrometry platform for quantitative protein biomarker and therapeutic protein measurement, serving pharmaceutical, biotech, diagnostic, and clinical reference laboratory customers via custom assay development, CRO analytical services, and a 350+ assay catalog.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunoaffinity mass spectrometry, targeted protein assays, biomarker quantification services, clinical proteomics assays, therapeutic antibody measurement
Industry4 codes
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Targeted Protein Assays & Clinical Proteomics Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Custom assay development services
TypeProfessional Services
Description

Development of bespoke SISCAPA assays for client-identified proteins including peptide selection, immuno-affinity reagent development, automated assay optimization and qualification, and implementation in various matrices.

siscapa.com
2CRO analytical services
TypeProfessional Services
Description

Non-GLP sample analysis and multiplex panel analysis combining novel and catalog assays for pharmaceutical and biotech clients.

siscapa.com
3Catalog assay menu
TypeOne Time License
Description

Over 350 SISCAPA assays developed against diverse protein biomarkers available for purchase, covering clinically-established protein targets including many FDA-cleared clinical markers.

siscapa.com
4Longitudinal dried blood spot studies
TypeProfessional Services
Description

DBS study support including mobile health components and wearable sensor integration for biomarker monitoring.

siscapa.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1LongitudeDX
Description

Proprietary platform for longitudinal measurement of protein biomarkers using dried blood spots (DBS), enabling researchers to accurately monitor endogenous and synthetic proteins in blood over time for disease dynamics and treatment efficacy insights.

siscapa.com
+1 more record
Core offering1 text field

SISCAPA Assay Technologies develops and delivers immunoaffinity-mass spectrometry assays (the SISCAPA platform) that combine specific anti-peptide antibody enrichment with targeted mass spectrometry detection to quantify protein biomarkers and therapeutic proteins. The company sells a catalog of 350+ SISCAPA assays, performs custom assay development, and runs CRO analytical services for pharmaceutical, biotech, and diagnostic clients, with extensions into longitudinal dried blood spot monitoring via its LongitudeDX sub-brand.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 350 SISCAPA assays developed against diverse protein biomarkers
+3 more records
Product overview1 text field

SISCAPA Assay Technologies offers a platform-based portfolio centered on immuno-affinity-mass spectrometry (IA-MS) assays for protein quantification. The core product is the SISCAPA Immuno-Affinity-MS workflow, which combines anti-peptide antibody enrichment with mass spectrometry detection to provide highly sensitive, specific, and multiplexed protein measurements. This core platform is extended through specialized assay panels (Inflammation, Oncology, Iron Metabolism), the LongitudeDX longitudinal monitoring sub-brand with its SampleDiary sampling system, and custom assay development and CRO analytical services. A strategic partnership with Biognosys extends the platform's accessibility into regulated clinical trial environments.

Product and service8 records
1SISCAPA Immuno-Affinity-MS Assays
CategoryCore Assay Platform
Description

Targeted protein quantification assays combining specific anti-peptide antibody enrichment with mass spectrometry detection, offering high sensitivity, specificity, and multiplexing capabilities for measuring protein drugs, targets, and biomarkers in various biological matrices for pharmaceutical, biotech, and diagnostic customers.

2SISCAPA Assay Development Services
CategoryCustom Services
Description

Custom assay development services including peptide selection, immuno-affinity reagent development and supply, automated assay optimization and qualification, and implementation in serum, dried blood spot, tissue, and other matrices with transfer to regulated CROs.

3CRO Analytical Services
CategoryAnalytical Services
Description

Contract research organization analytical services providing non-GLP sample analysis, multiplex panels combining novel and catalog assays, and longitudinal dried blood spot studies for pharmaceutical and biotech clients.

4LongitudeDX
CategoryLongitudinal Monitoring Platform
Description

A longitudinal health monitoring platform utilizing dried blood spot sampling combined with SISCAPA assay panels for high-frequency, personalized tracking of protein biomarkers over time, integrated with mobile health components and wearable sensor data.

5SampleDiary
CategorySampling System
Description

A compact, user-friendly dried blood spot sampling system augmented with automated contextual information gathering from wearable sensors, enabling high-frequency biomarker tracking for personalized health monitoring.

6Inflammation Panel
CategoryMultiplex Assay Panel
Description

A multiplexed panel of inflammation markers including CRP, SAA, orosomucoid, LPS-binding protein, mannose-binding lectin, haptoglobin, complement C3, fibrinogen, IgM, and myeloperoxidase for tracking inflammatory responses across clinically relevant timescales.

7Oncology Panel
CategoryMultiplex Assay Panel
Description

A panel of cancer-related protein biomarkers including FDA-cleared markers (AFP, CEA, PSA, mesothelin) and drug target proteins (PD-1, BTK) for oncology research and clinical monitoring.

8Iron Metabolism Panel
CategoryMultiplex Assay Panel
Description

An integrated panel measuring iron metabolism components including transferrin, soluble transferrin receptor, hemopexin, ferritin, hepcidin, ferroportin, hemoglobin, and haptoglobin for studying conditions like anemia, thalassemia, and neurodegeneration with brain iron accumulation.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-12
Description

SISCAPA formed a collaboration with Biognosys to develop ultra-sensitive targeted protein assays for clinical research. The partnership combines SISCAPA's immuno-enrichment technology with Biognosys' proteomics expertise and infrastructure. Biognosys provides state-of-the-art infrastructure and regulatory rigor to make SISCAPA assays broadly accessible in regulated environments, enabling deployment across the full drug development pipeline from preclinical studies to clinical trials.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with Bruker expanded hybrid metabolomics offerings. This collaboration complements SISCAPA's targeted proteomics capabilities by enabling combined multiomics solutions for discovery, translational, and clinical research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with Biocrates expanded hybrid metabolomics offerings alongside Bruker. This collaboration enables combined multiomics solutions for biomarker discovery and clinical research applications.

Strategic tierCoreTypeTechnology or Integration
Description

LongitudeDX is a SISCAPA product platform (separate website at longitudedx.com) that revolutionizes longitudinal measurement of protein biomarkers using dried blood spots. The platform integrates proprietary techniques with mobile health components and wearable sensors for comprehensive biomarker tracking over time.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provides targeted protein biomarker discovery and measurement using proximity extension assay (PEA) technology coupled with NGS readout. A direct competitor to SISCAPA in high-multiplex targeted proteomics for pharma/biotech R&D; now owned by Thermo Fisher, giving it substantially greater scale.

TypeDirect peer
Description

Developer of the Simoa single-molecule array platform for ultra-sensitive protein detection in blood and biofluids. Competes with SISCAPA in high-sensitivity protein biomarker measurement for neurology, oncology, and infectious disease applications.

TypeDirect peer
Description

Operates the SomaScan aptamer-based proteomics platform measuring thousands of proteins simultaneously. A direct peer in targeted protein biomarker profiling for pharma R&D, clinical trials, and translational research, now part of Standard BioTools.

TypeDirect peer
Description

Offers MULTI-ARRAY electrochemiluminescence immunoassays for multiplexed protein biomarker quantification. Competes with SISCAPA in pharma/biotech biomarker and PK/PD assays where high sensitivity and multiplexing are required.

TypeBroad incumbent
Description

Diversified life science tools company with ProteinSimple branded analytical instruments, reagents, and the Simple Western platform. A broad incumbent serving proteomics and protein analysis customers, with substantially greater resources than SISCAPA.

TypeDirect peer
Description

Bioanalytical CRO specializing in large-molecule PK/PD, immunogenicity, and biomarker assays for biologics, biosimilars, and gene/cell therapies. A direct peer to SISCAPA's CRO analytical services targeting pharma and biotech customers.

TypeDirect peer
Description

Contract research organization providing bioanalytical services, including LC-MS/MS-based protein quantification and biomarker assays. Direct peer to SISCAPA's CRO analytical services for pharma/biotech drug development programs.

TypeBroad incumbent
Description

Global bioanalytical laboratory network offering LC-MS/MS, immunoassay, and biomarker services for pharma and biotech. A broad incumbent providing similar CRO services to SISCAPA but at significantly larger scale.

TypeBroad incumbent
Description

Developer of reagents, assays, and integrated systems for protein analysis, cell biology, and molecular diagnostics. A broad incumbent serving pharma/biotech researchers with bioanalytical tools that overlap with SISCAPA's workflow reagents.

TypeOthers
Description

Global supplier of high-quality protein research tools, including antibodies and immunoassay reagents. Related ecosystem participant whose reagents and kits are often used alongside SISCAPA-style immuno-affinity workflows in protein research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SISCAPA Assay Technologies

Targeted Protein Assays & Clinical Proteomics Servicessiscapa.com

SISCAPA Assay Technologies develops and commercializes the SISCAPA immuno-affinity mass spectrometry platform for quantitative protein biomarker and therapeutic protein measurement, serving pharmaceutical, biotech, diagnostic, and clinical reference laboratory customers via custom assay development, CRO analytical services, and a 350+ assay catalog.

What SISCAPA Assay Technologies does

SISCAPA Assay Technologies, Inc. is a Washington, DC-based private proteomics company founded in 2011 that develops and commercializes the SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) immuno-affinity mass spectrometry platform for quantitative measurement of protein biomarkers and therapeutic proteins. The technology combines high-affinity anti-peptide antibody enrichment of proteolytically derived surrogate peptides with stable isotope-labeled internal standards and targeted mass spectrometry detection, enabling interference-free quantification across a >10^10-fold dynamic range, sub-ng/mL sensitivity in complex matrices, and multiplexing of up to ~50 assays in a single run. The company has built a catalog of more than 350 validated assays against diverse protein biomarkers, including FDA-cleared clinical markers such as thyroglobulin, where its clinical test has produced over 150,000 patient results through reference laboratories worldwide.

SISCAPA monetizes primarily through professional services: custom assay development (peptide selection, antibody reagent development, automated workflow optimization, and transfer to client CROs) and CRO-style analytical services including non-GLP sample analysis and multiplex panel execution. It also sells catalog assays outright and operates the LongitudeDX sub-brand, which combines dried blood spot sampling, wearable sensor integration, and the SampleDiary module for high-frequency longitudinal biomarker monitoring. Customers are pharmaceutical and biotechnology companies, gene therapy developers, diagnostic firms, academic researchers, and clinical reference laboratories. A wholly-owned Canadian subsidiary supports North American operations, and a June 2026 strategic collaboration with Biognosys extends assay accessibility into regulated clinical trial environments through Biognosys' CRO infrastructure.

The company is founder-controlled (N. Leigh Anderson, CEO and inventor of SISCAPA; Terry Pearson, CSO; Constance Seniff, VP Business Operations), with board oversight from seasoned diagnostics operators including a former Olink Proteomics chair and a biotech entrepreneur-investor. Capitalization has been modest: three disclosed funding rounds totaling roughly $3.56M between 2012 and 2025. The company competes on scientific depth and assay breadth rather than scale, with no publicly disclosed revenue and no AI/ML layer on top of its chemistry platform.

SISCAPA Assay Technologies firmographics

Firmographics
Name
SISCAPA Assay Technologies
Legal name
SISCAPA Assay Technologies, Inc.
Website
https://siscapa.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
SISCAPA Assay Technologies develops and commercializes the SISCAPA immuno-affinity mass spectrometry platform for quantitative protein biomarker and therapeutic protein measurement, serving pharmaceutical, biotech, diagnostic, and clinical reference laboratory customers via custom assay development, CRO analytical services, and a 350+ assay catalog.
Ownership category
akta.pro rank

SISCAPA Assay Technologies industry classification

Industry
Product category
Targeted Protein Assays & Clinical Proteomics Services
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories

Keywords

  • Immunoaffinity mass spectrometry
  • Targeted protein assays
  • Biomarker quantification services
  • Clinical proteomics assays
  • Therapeutic antibody measurement

Where SISCAPA Assay Technologies is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

SISCAPA Assay Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Custom assay development services: Development of bespoke SISCAPA assays for client-identified proteins including peptide selection, immuno-affinity reagent development, automated assay optimization and qualification, and implementation in various matrices.
  2. CRO analytical services: Non-GLP sample analysis and multiplex panel analysis combining novel and catalog assays for pharmaceutical and biotech clients.
  3. Catalog assay menu: Over 350 SISCAPA assays developed against diverse protein biomarkers available for purchase, covering clinically-established protein targets including many FDA-cleared clinical markers.
  4. Longitudinal dried blood spot studies: DBS study support including mobile health components and wearable sensor integration for biomarker monitoring.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

SISCAPA Assay Technologies product offering

Product offering

Core offering

SISCAPA Assay Technologies develops and delivers immunoaffinity-mass spectrometry assays (the SISCAPA platform) that combine specific anti-peptide antibody enrichment with targeted mass spectrometry detection to quantify protein biomarkers and therapeutic proteins. The company sells a catalog of 350+ SISCAPA assays, performs custom assay development, and runs CRO analytical services for pharmaceutical, biotech, and diagnostic clients, with extensions into longitudinal dried blood spot monitoring via its LongitudeDX sub-brand.

Product overview

SISCAPA Assay Technologies offers a platform-based portfolio centered on immuno-affinity-mass spectrometry (IA-MS) assays for protein quantification. The core product is the SISCAPA Immuno-Affinity-MS workflow, which combines anti-peptide antibody enrichment with mass spectrometry detection to provide highly sensitive, specific, and multiplexed protein measurements. This core platform is extended through specialized assay panels (Inflammation, Oncology, Iron Metabolism), the LongitudeDX longitudinal monitoring sub-brand with its SampleDiary sampling system, and custom assay development and CRO analytical services. A strategic partnership with Biognosys extends the platform's accessibility into regulated clinical trial environments.

Differentiator

Problem solved

Functional benefit

Brands

  • LongitudeDX: Proprietary platform for longitudinal measurement of protein biomarkers using dried blood spots (DBS), enabling researchers to accurately monitor endogenous and synthetic proteins in blood over time for disease dynamics and treatment efficacy insights.
  • SampleDiary

Products and services

  • SISCAPA Immuno-Affinity-MS Assays Targeted protein quantification assays combining specific anti-peptide antibody enrichment with mass spectrometry detection, offering high sensitivity, specificity, and multiplexing capabilities for measuring protein drugs, targets, and biomarkers in various biological matrices for pharmaceutical, biotech, and diagnostic customers.
  • SISCAPA Assay Development Services Custom assay development services including peptide selection, immuno-affinity reagent development and supply, automated assay optimization and qualification, and implementation in serum, dried blood spot, tissue, and other matrices with transfer to regulated CROs.
  • CRO Analytical Services Contract research organization analytical services providing non-GLP sample analysis, multiplex panels combining novel and catalog assays, and longitudinal dried blood spot studies for pharmaceutical and biotech clients.
  • LongitudeDX A longitudinal health monitoring platform utilizing dried blood spot sampling combined with SISCAPA assay panels for high-frequency, personalized tracking of protein biomarkers over time, integrated with mobile health components and wearable sensor data.
  • SampleDiary A compact, user-friendly dried blood spot sampling system augmented with automated contextual information gathering from wearable sensors, enabling high-frequency biomarker tracking for personalized health monitoring.
  • Inflammation Panel A multiplexed panel of inflammation markers including CRP, SAA, orosomucoid, LPS-binding protein, mannose-binding lectin, haptoglobin, complement C3, fibrinogen, IgM, and myeloperoxidase for tracking inflammatory responses across clinically relevant timescales.
  • Oncology Panel A panel of cancer-related protein biomarkers including FDA-cleared markers (AFP, CEA, PSA, mesothelin) and drug target proteins (PD-1, BTK) for oncology research and clinical monitoring.
  • Iron Metabolism Panel An integrated panel measuring iron metabolism components including transferrin, soluble transferrin receptor, hemopexin, ferritin, hepcidin, ferroportin, hemoglobin, and haptoglobin for studying conditions like anemia, thalassemia, and neurodegeneration with brain iron accumulation.

Quantifiable outcome

  • Over 350 SISCAPA assays developed against diverse protein biomarkers
  • +3 more outcomes

Companies that use SISCAPA Assay Technologies

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

SISCAPA Assay Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SISCAPA Assay Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • BiognosyscoreStrategic or Co-development Partner · 12 June 2026SISCAPA formed a collaboration with Biognosys to develop ultra-sensitive targeted protein assays for clinical research. The partnership combines SISCAPA's immuno-enrichment technology with Biognosys' proteomics expertise and infrastructure. Biognosys provides state-of-the-art infrastructure and regulatory rigor to make SISCAPA assays broadly accessible in regulated environments, enabling deployment across the full drug development pipeline from preclinical studies to clinical trials.
  • BrukerminorStrategic or Co-development PartnerPartnership with Bruker expanded hybrid metabolomics offerings. This collaboration complements SISCAPA's targeted proteomics capabilities by enabling combined multiomics solutions for discovery, translational, and clinical research.
  • BiocratesminorStrategic or Co-development PartnerPartnership with Biocrates expanded hybrid metabolomics offerings alongside Bruker. This collaboration enables combined multiomics solutions for biomarker discovery and clinical research applications.
  • LongitudeDXcoreTechnology or IntegrationLongitudeDX is a SISCAPA product platform (separate website at longitudedx.com) that revolutionizes longitudinal measurement of protein biomarkers using dried blood spots. The platform integrates proprietary techniques with mobile health components and wearable sensors for comprehensive biomarker tracking over time.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

SISCAPA Assay Technologies competitors and assessment

Company assessment

Direct peers

  • Olink Proteomics: Provides targeted protein biomarker discovery and measurement using proximity extension assay (PEA) technology coupled with NGS readout. A direct competitor to SISCAPA in high-multiplex targeted proteomics for pharma/biotech R&D; now owned by Thermo Fisher, giving it substantially greater scale.
  • Quanterix: Developer of the Simoa single-molecule array platform for ultra-sensitive protein detection in blood and biofluids. Competes with SISCAPA in high-sensitivity protein biomarker measurement for neurology, oncology, and infectious disease applications.
  • SomaLogic (Standard BioTools): Operates the SomaScan aptamer-based proteomics platform measuring thousands of proteins simultaneously. A direct peer in targeted protein biomarker profiling for pharma R&D, clinical trials, and translational research, now part of Standard BioTools.
  • Meso Scale Diagnostics: Offers MULTI-ARRAY electrochemiluminescence immunoassays for multiplexed protein biomarker quantification. Competes with SISCAPA in pharma/biotech biomarker and PK/PD assays where high sensitivity and multiplexing are required.
  • BioAgilytix: Bioanalytical CRO specializing in large-molecule PK/PD, immunogenicity, and biomarker assays for biologics, biosimilars, and gene/cell therapies. A direct peer to SISCAPA's CRO analytical services targeting pharma and biotech customers.
  • Celerion: Contract research organization providing bioanalytical services, including LC-MS/MS-based protein quantification and biomarker assays. Direct peer to SISCAPA's CRO analytical services for pharma/biotech drug development programs.

Broad incumbents

  • Bio-Techne: Diversified life science tools company with ProteinSimple branded analytical instruments, reagents, and the Simple Western platform. A broad incumbent serving proteomics and protein analysis customers, with substantially greater resources than SISCAPA.
  • Eurofins Bioanalytical Services: Global bioanalytical laboratory network offering LC-MS/MS, immunoassay, and biomarker services for pharma and biotech. A broad incumbent providing similar CRO services to SISCAPA but at significantly larger scale.
  • Promega: Developer of reagents, assays, and integrated systems for protein analysis, cell biology, and molecular diagnostics. A broad incumbent serving pharma/biotech researchers with bioanalytical tools that overlap with SISCAPA's workflow reagents.

Others

  • Abcam: Global supplier of high-quality protein research tools, including antibodies and immunoassay reagents. Related ecosystem participant whose reagents and kits are often used alongside SISCAPA-style immuno-affinity workflows in protein research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SISCAPA Assay Technologies social profiles

Digital presence

SISCAPA Assay Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SISCAPA Assay Technologies leadership team

Management profile

Number of profiles

Profiles9 records

SISCAPA Assay Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SISCAPA Assay Technologies funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SISCAPA Assay Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SISCAPA Assay Technologies

What does SISCAPA Assay Technologies do?

SISCAPA Assay Technologies develops and delivers immunoaffinity-mass spectrometry assays (the SISCAPA platform) that combine specific anti-peptide antibody enrichment with targeted mass spectrometry detection to quantify protein biomarkers and therapeutic proteins. The company sells a catalog of 350+ SISCAPA assays, performs custom assay development, and runs CRO analytical services for pharmaceutical, biotech, and diagnostic clients, with extensions into longitudinal dried blood spot monitoring via its LongitudeDX sub-brand.

Is SISCAPA Assay Technologies a public or private company?

SISCAPA Assay Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was SISCAPA Assay Technologies founded?

SISCAPA Assay Technologies was founded in 2011. It employs 1 to 10 people.

Where is SISCAPA Assay Technologies based?

SISCAPA Assay Technologies is headquartered in Washington, United States, in the North America region.

How does SISCAPA Assay Technologies make money?

Four revenue lines are on record. Custom assay development services are the primary driver. The others are CRO analytical services, catalog assay menu and longitudinal dried blood spot studies.

Who are SISCAPA Assay Technologies's main competitors?

Direct peers on record are Olink Proteomics, Quanterix, SomaLogic (Standard BioTools), Meso Scale Diagnostics, BioAgilytix and Celerion. Broad incumbents are Bio-Techne, Eurofins Bioanalytical Services and Promega. Abcam is listed as an others.

Does SISCAPA Assay Technologies have an API?

No public API is recorded for SISCAPA Assay Technologies.

What industry is SISCAPA Assay Technologies in?

SISCAPA Assay Technologies's product category is Targeted Protein Assays & Clinical Proteomics Services. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals